GYKI 38233

Drug Profile

GYKI 38233

Alternative Names: B GYKI 38233; Restacorin; TYB 3823

Latest Information Update: 07 Mar 2007

Price : $50

At a glance

  • Originator IVAX Drug Research Institute
  • Developer Biogal; IVAX Drug Research Institute
  • Class Class Ic antiarrhythmics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 30 May 2001 Profile reviewed but no significant changes made
  • 03 Dec 1998 No-Development-Reported for Arrhythmias in Netherlands (PO)
  • 03 Dec 1998 No-Development-Reported for Arrhythmias in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top